Five Structural Shifts Reshaping the European Market

Five Structural Shifts Reshaping the European Market

The European pharmaceutical and nutraceutical markets are navigating a period of significant structural change.

Regulatory tightening, evolving patient expectations, and the post-pandemic acceleration of self-care are collectively reshaping what it means to bring a finished dosage form to market. At the core of this transformation lies an often-underestimated variable: excipient strategy.

1. The Patient-Centric Turn

Consumers are no longer passive recipients of pharmaceutical products.

Across Europe, an ageing population combined with growing health literacy is pushing manufacturers to prioritize tolerability, ease of swallowing, and taste masking alongside efficacy. Older people are the fastest growing population group in Europe and are the main users of medicines — a dynamic that EMA has formally integrated into its medicines development framework.

This trend is particularly visible in the OTC and nutraceutical segments, where purchase decisions are made by end-users without medical intermediaries. According to Mordor Intelligence, the European OTC drugs market is projected to reach USD 46.44 billion by 2031 — with gummies and dissolvable films growing at 10.83% annually as manufacturers respond to pill-fatigued consumers.

The practical implication for formulators is clear: excipients are no longer purely functional infrastructure. Their sensory properties, their compatibility with clean-label positioning, and their contribution to product elegance have become genuine differentiators in a competitive shelf environment. As ONdrugDelivery notes, leveraging specialised excipients is now the primary lever for developing more patient-centric formulations that improve outcomes for older patients.

2. Clean-Label Pressure Reaches Solid Dosage

What began as a trend in food and cosmetics has steadily migrated into pharmaceutical and nutraceutical formulation.

Consumers — and increasingly, health practitioners — scrutinize ingredient lists. Excipients derived from synthetic or poorly-understood origins face growing reputational risk, even when regulatory compliance is assured. German consumers value product quality and often favour herbal or natural alternatives, which has encouraged companies to invest in clean-label and plant-based formulations.

This has accelerated interest in excipients with well-established origins, transparent safety profiles, and natural or semi-natural derivation. Starches, polyols, and plant-derived functional ingredients benefit from this dynamic, provided they can deliver the technical performance that complex formulations require.

3. The Rise of Direct Compression and Continuous Manufacturing

Process efficiency is exerting its own pressure on excipient selection.

As manufacturers across Europe migrate toward direct compression (DC) and continuous manufacturing platforms — driven by both cost optimization and regulatory encouragement — the demand for excipients offering outstanding flowability, compressibility, and batch-to-batch consistency has intensified sharply. Both the FDA and EMA actively encourage continuous manufacturing as it aligns with the Quality by Design (QbD) paradigm. ICH Q13 — adopted by EMA in July 2023 — now provides the harmonized regulatory framework for its implementation across Europe.

Traditional wet granulation workflows remain relevant, but the economics of DC are compelling. Formulators consequently need excipients that perform reliably at high throughput, with minimal sensitivity to environmental variables such as humidity — a meaningful consideration for production facilities across Northern Europe and the British Isles.

4. Supply Chain Resilience as a Strategic Imperative

The disruptions of recent years exposed significant vulnerabilities in pharmaceutical ingredient supply chains.

European manufacturers, previously reliant on concentrated sourcing from a handful of global regions, have since prioritized supplier diversification, regional availability, and long-term partnership stability. As Safic-Alcan's analysis of supply chain resilience in the pharmaceutical industry highlights, selecting at least two or three sources of key ingredients — and relying on distributors with direct local presence in key sourcing markets — is now a strategic necessity, not a contingency measure.

For excipient procurement teams, this translates into a preference for distributors capable of covering multiple European markets under a single partnership framework — reducing administrative overhead while guaranteeing consistent quality standards and regulatory documentation across jurisdictions.

5. Nutraceuticals: A Growing Appetite for Pharmaceutical-Grade Standards

The boundary between nutraceuticals and pharmaceuticals continues to blur.

As supplement manufacturers position their products in therapeutic adjacencies — digestive health, cognition, immunity — they increasingly adopt pharmaceutical-grade formulation standards, including the use of excipients validated for drug applications. As explored in our article on evidence-based nutraceuticals, for premium or science-driven products, investing in ingredients supported by in-vivo and clinical research has become essential to secure regulatory compliance and market trust.

This convergence creates new sourcing requirements: excipients that are technically suited to both regulated pharmaceutical manufacturing and the faster, more agile development cycles typical of the nutraceutical industry. Multi-functional excipients capable of serving as fillers, binders, and flow agents simultaneously are particularly valued in this context.